Zetagen Therapeutics, Inc. Announces European Patent for the Treatment of Stimulating Bone Growth

• U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
• Latest patent issuance follows previous patents for methods in stimulating bone growth, promote controlled bone creation and repair of large segmental bone defects using ZetaMet™ (Zeta-BC-003)
• Company’s intellectual property pipeline targets other oncologic treatments for Skeletal- Related Events (SRE’s) and osteologic interventions

April 28, 2021, (Syracuse, New York) - Zetagen Therapeutics, Inc. a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions today announced that the European Patent Office issued Patent. No. 3148517 to the Company. The patent, entitled Composition and Methods to Promote Bone Formation, covers the use of methods for stimulating bone growth using its small molecule, ZetaMet™ (Zeta-BC-003). ZetaMet™ (Zeta-BC-003) is a synthetic, small-molecule, inductive biologic, delivered via a drug-eluting implant on an osteopromotive carrier.

The European patent follows the previously issued Australian Patent. No. 2015267006, U.S. Patent. No. 10208306 and South African PCT. 201700029 covering the use of a method for stimulating bone growth using a small molecule and U.S. Patent Nos. 102656437 covering the use of methods to promote controlled bone creation and destruction as a means to repair large bone segmental defects.

“I am pleased with both our Clinical and IP Global progress to bring our novel technologies to the worldwide market, so patients suffering from painful metastatic lesions have access to our products”, said Joe C. Loy, CEO Zetagen Therapeutics, Inc.

The new patent is part of an expanding and comprehensive portfolio of patents, patent applications and other intellectual property covering the composition, synthesis, manufacturing, formulations and uses for the treatment of a variety of metastatic bone lesions. Zetagen exclusively licensed its platform technology from the State University of New York in 2016.